1. April 2022 : Neuigkeiten am Corona Horizont

Press Release
April 1, 2022

💡Neuigkeiten am Corona Horizont:

🦠 Das Paul-Ehrlich-Institut hat in seinem aktuellen Newsletter 03/2022 von 1 April 2022 folgende Neuigkeiten zu Neuzulassungen in der Covid19 Prophylaxe und Impfstoffe bekanntgegeben:

Antrag auf bedingte Zulassung für den proteinbasierten COVID-19-Impfstoffkandidaten Vidprevtyn gestellt
👉https://lnkd.in/e3KQJqdE

Rolling-Review für Booster-Impfstoff COVID-19 Vaccine HIPRA hat begonnen
👉https://lnkd.in/eChgTDbd

Zulassung der monoklonalen Antikörper-Kombination Evusheld (Tixagevimab und Cilgavimab) zur COVID-19-Prophylaxe erteilt
👉https://lnkd.in/ef9aCnM2

Schedule Your Expert Hour

Get INSIGHTS into the strategies you need for a successful clinical trial!

Share This Post

More To Explore

Avoid CTIS submission mistakes when applying for clinical trials in drug development

General

Most Common CTIS Submission Mistakes

Learn the most common CTIS submission mistakes in Part I and Part II documents. Submit your EU CTIS without delays.

Ghazaleh Gouya 21.05.2026

Early stage companies need to know when to interact with the European Medicines Agency (EMA)

General

How Early-Stage Biotech Companies Should First Engage with ITF EMA

Early-stage biotech companies often contact the EMA too late. Learn when and how to request an EMA Innovation Task Force (ITF) meeting, how it differs from Scientific Advice, and what to prepare before your first ITF EMA engagement.

Ghazaleh Gouya 21.05.2026

1. April 2022 : Neuigkeiten am Corona Horizont

Schedule Your Expert Hour

Get INSIGHTS into the strategies you need for a successful clinical trial!

Share This Post

More To Explore

Most Common CTIS Submission Mistakes

How Early-Stage Biotech Companies Should First Engage with ITF EMA

Navigate

Follow Us

Book Expert Hour

Dr. Nora Gedeon

Data Protection Officer (DPO) and Vendor Manager